Consumer and healthcare agency Moon Rabbit has been named agency of record for OPNT003, nasal nalmefene, from Opiant Pharmaceuticals. Nasal nalmefene is a product currently being evaluated in clinical trials for the treatment of opioid overdose. Moon Rabbit will be responsible for supporting commercial preparations and, if approved by the FDA, launch of OPNT003 in the U.S.
Moon Rabbit managing partner John Tenaglia said “Opiant’s mission to develop new medicines for addictions and drug overdose represent a critical and essential advancement in the public health realm. Its potential new treatment for opioid overdose is something we are incredibly passionate about."
Matt Ruth, Chief Commercial Officer, Opiant, said: “When looking for an agency to support our commercialization efforts for OPNT003 in the U.S., the Moon Rabbit team showed us a brave strategy, powerful creative thinking, and an understanding of the human decisions that underlie the opioid overdose crisis and how we as a company can play a role."